Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 1/2 3Phase 3 2Phase 1 2Phase 2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Dermatologic 2Thoracic 1

Conditions

Melanoma 778Carcinoma, Non-Small-Cell Lung 198Lymphoma, T-Cell, Cutaneous 171Carcinoma, Renal Cell 139Neoplasms 130Mycosis Fungoides 120Breast Neoplasms 114Lymphoma, Large B-Cell, Diffuse 112Colorectal Neoplasms 111Lymphoma, Non-Hodgkin 110Sezary Syndrome 109Lymphoma, Follicular 107Neoplasm Metastasis 105Lymphoma 103Leukemia, Lymphocytic, Chronic, B-Cell 103Lymphoma, Mantle-Cell 100Lymphoma, B-Cell, Marginal Zone 98Hodgkin Disease 98Precursor Cell Lymphoblastic Leukemia-Lymphoma 97Burkitt Lymphoma 94Squamous Cell Carcinoma of Head and Neck 92Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 92Lymphoma, Large-Cell, Immunoblastic 86Lymphoma, Large-Cell, Anaplastic 86Ovarian Neoplasms 84Lung Neoplasms 80Immunoblastic Lymphadenopathy 79Sarcoma 67Pancreatic Neoplasms 65Head and Neck Neoplasms 64

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Melanoma, Cutaneous Malignant × Dermatologic × Clear all
NCT04620603 2026-05-05

Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer

Case Comprehensive Cancer Center

Phase 1 Active not recruiting
5 enrolled
DermatologicGenitourinary

Melanoma, Cutaneous Malignant, Carcinoma, Renal Cell

NCT05479812 2026-02-09

Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

Werewolf Therapeutics, Inc.

Phase 1 Active not recruiting
150 enrolled
DermatologicGenitourinaryThoracic

Melanoma, Cutaneous Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡